Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 536 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo gel Clear all
Completed Phase 2 Interventional

Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

NCT06331624
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
Tazarotene (GRI-0621), Placebo
Drug
Lead sponsor
GRI Bio Operations, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Self-Administered Lidocaine Gel for Pain Management With IUD Insertion

NCT02738203
View directory record Official record
Conditions
IUD Insertion
Interventions
Vaginal 2% Lidocaine, Surgical Lubricant Jelly
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 7, 2026, 2:32 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Spectroscopic Imaging at 4T: A Drug Challenge Study

NCT01577706
View directory record Official record
Conditions
AOD Effects and Consequences
Interventions
Alprazolam, Dextroamphetamine, Placebo
Drug · Other
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

NCT04797793
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.1%, Placebo Control, Differin® Gel (Adapalene 0.1%, Galderma)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
978 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 7, 2026, 2:32 PM EDT
Terminated Not applicable Interventional

Omega-3 Fatty Acid Supplements and Dry Eye

NCT01213342
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Omega-3 Fatty Acid, Soybean Soft Gels
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne

NCT01701024
View directory record Official record
Conditions
Acne
Interventions
ACYC, ACYC vehicle
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Mobile, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vitamin D in Postmenopausal Women at High Risk for Breast Cancer

NCT00859651
View directory record Official record
Conditions
Breast Cancer
Interventions
Cholecalciferol, Placebo capsule
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 7, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional Results available

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

NCT04570956
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
Interventions
Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

NCT06673641
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

NCT02005666
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel, Placebo
Drug
Lead sponsor
Zydus Lifesciences Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Multisite Controlled Trial of Cocaine Vaccine

NCT00969878
View directory record Official record
Conditions
Cocaine Dependence
Interventions
TA-CD Vaccination, Placebo Injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blueberry-protein Supplementation and Exercise

NCT05596500
View directory record Official record
Conditions
Inflammatory Response
Interventions
Blueberry-protein gel, Blueberry gel, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73

NCT01592214
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Placebo, XF-73 in 2% Klucel gel, XF-73 in 4% Klucel gel
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Anaheim, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study Of The Caya® Diaphragm Used With ContraGel®

NCT02462954
View directory record Official record
Conditions
Contraception
Interventions
ContraGel, HEC Universal Placebo gel
Device
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 7, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional Results available

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

NCT00515112
View directory record Official record
Conditions
Prostate Cancer
Interventions
AndroGel, placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Results available

Acthar Gel for Active Systemic Lupus Erythematosus (SLE)

NCT02953821
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Acthar Gel, Placebo Gel
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Hemet, California • Upland, California • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

NCT04675788
View directory record Official record
Conditions
Long QT Syndrome, Abnormalities, Drug-Induced
Interventions
Progesterone, Ibutilide, Testosterone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
50 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 7, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional Results available

Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis

NCT00075023
View directory record Official record
Conditions
Graft-versus-Host Disease, Stomatitis
Interventions
Thalidomide Gel, Placebo Gel
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 7, 2026, 2:32 PM EDT
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects

NCT02594254
View directory record Official record
Conditions
Dental Caries
Interventions
C16G2 Gel, Placebo
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
10
States / cities
Imperial Beach, California • Indianapolis, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

NCT03614663
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
ZYN002 - Cannabidiol Transdermal Gel, Placebo Transdermal Gel
Drug · Other
Lead sponsor
Zynerba Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124552
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001 Botulinum toxin type A (Dose A), RT001 Botulinum Toxin Type A (Dose B), Vehicle, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 7, 2026, 2:32 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

NCT05276401
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers
Interventions
5% Bisphosphocin Topical Gel, Placebo Topical Gel, 10% Bisphosphocin Topical Gel
Drug
Lead sponsor
Lakewood-Amedex Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
5
States / cities
Jonesboro, Arkansas • Fresno, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 7, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities

NCT00493051
View directory record Official record
Conditions
Diabetic Foot
Interventions
GAM501, Placebo, Standard of care
Biological · Other
Lead sponsor
Tissue Repair Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 7, 2026, 2:32 PM EDT